MOTS-c
$64.99
10 MG

In stock
Buy Tesamorelin peptide at Velora Research — a synthetic GHRH analog supplied as a lyophilized research compound in 10mg vials. Each batch is independently HPLC- and mass-spec-verified at ≥99% purity, with a downloadable Certificate of Analysis tied to the lot number. Tesamorelin cost at Velora: $60 per 10mg vial, with free US shipping over $200. Strictly for in vitro laboratory research — not for human or veterinary use, and not the same product as EGRIFTA SV®.
Specifications
Tesamorelin is a synthetic 44-amino-acid peptide analog of growth hormone-releasing hormone (GHRH 1-44), modified with an N-terminal trans-3-hexenoyl group that improves stability against enzymatic degradation. Velora Research supplies tesamorelin as a lyophilized research peptide for in vitro and preclinical investigation by qualified laboratories and research professionals.
Every Tesamorelin 10mg vial supplied by Velora is independently verified by a third-party analytical laboratory using high-performance liquid chromatography (HPLC) and mass spectrometry. The batch-specific Certificate of Analysis is published on our COAs page and linked from this product page so researchers can confirm identity, purity, and molecular integrity before placing the compound into a study.
Published research describes tesamorelin as a GHRH receptor agonist that, in preclinical and clinical models, binds pituitary somatotroph cells and stimulates endogenous growth hormone (GH) secretion in a pulsatile, physiologic pattern. Downstream, this is associated with elevations in insulin-like growth factor 1 (IGF-1).
EGRIFTA SV® is a registered trademark of Theratechnologies. Velora Research’s Tesamorelin product is a research peptide supplied for in vitro and preclinical investigation only and is not affiliated with, endorsed by, or equivalent to EGRIFTA SV®. It is not for human use.
| Attribute | Specification |
| Research name | Tesamorelin (research peptide) |
| Chemical class | Stabilized GHRH (1-44) analog |
| Sequence | trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 |
| Available size | 10mg |
| Form | Lyophilized white powder |
| Purity | ≥99% (HPLC verified) |
| Molecular formula | C221H366N72O67S |
| Molecular weight | ~5135.87 g/mol |
| CAS number | 218949-48-5 |
| Storage (lyophilized) | -20°C, sealed, dry, dark |
| Storage (reconstituted) | 2-8°C, single-use aliquots recommended |
| Verification | Independent third-party HPLC + mass spectrometry per batch |
| COA access | Batch-specific COA at verify.janoshik.com (linked from this page) |
Velora Research lists Tesamorelin 10mg at a transparent, single-tier price so research buyers can plan procurement without negotiating per inquiry:
| Vial size | Tesamorelin cost (USD) | Best for |
| 10mg | $60.00 | Pilot studies, receptor-binding assays, single-protocol pilots, and most preclinical research designs |
Tesamorelin cost can vary widely across research-peptide suppliers — from under $50 for vendors that don’t publish testing data, to several hundred dollars for clinical-grade Egrifta SV®. Velora’s $60 price reflects a research-grade compound that is independently HPLC- and mass-spec-verified at ≥99% purity, with a batch-specific COA accessible from the product page. Free US shipping applies on orders over $200, and most orders ship within 1–2 business days.
In a category where vendor quality varies dramatically, five things separate Velora Research from the field:
Velora Research’s Tesamorelin ships as a lyophilized powder. For in vitro studies, researchers typically reconstitute with bacteriostatic water (0.9% benzyl alcohol) at a concentration matched to the assay protocol. A common pilot ratio for a 10mg vial is 2 mL of BAC water, yielding a 5 mg/mL stock solution — adjust per your study design.
Velora Research supplies bacteriostatic water as a separate product. Please refer to the peer-reviewed literature for protocol-specific reconstitution and handling parameters.
Researchers evaluating Tesamorelin for purchase often compare it to other growth-hormone-axis research peptides. Summary of how the three differ at the mechanism level, drawn from published research:
| Attribute | Tesamorelin | Sermorelin | Ipamorelin |
| Class | Stabilized GHRH (1-44) analog | Native GHRH fragment (1-29) | Selective GHRP (ghrelin receptor) |
| Receptor target | GHRH receptor | GHRH receptor | Ghrelin / GHS-R1a |
| Sequence length | 44 amino acids | 29 amino acids | 5 amino acids |
| Half-life | ~25–40 min | ~10–20 min | ~2 hours |
| FDA status (as of 2026) | Approved as EGRIFTA SV® (HIV lipodystrophy) | Not approved | Not approved |
| Mechanism profile in research | Sustained GHRH-receptor signaling | Short-acting GHRH-receptor signaling | Pulsatile, selective GH release without cortisol/prolactin spike |
Figures are drawn from published preclinical and clinical literature and are provided strictly for research-context comparison. Velora Research’s Tesamorelin, Sermorelin, and Ipamorelin products are supplied as research peptides for in vitro and preclinical investigation only — not as therapeutic products.
No. EGRIFTA SV® (tesamorelin acetate, Theratechnologies) is an FDA-approved injectable medication for HIV-associated lipodystrophy. Velora Research supplies tesamorelin as a research peptide for in vitro and preclinical investigation only. The two products are not interchangeable; Velora’s product is not a clinical or therapeutic product and is not for human use.
Velora Research lists Tesamorelin 10mg at $60.00 USD. Free US shipping applies on orders over $200. The tesamorelin cost reflects a research-grade compound with batch-specific HPLC and mass-spec verification — the COA is downloadable from the product page.
No. The tesamorelin sold by Velora Research is supplied strictly for in vitro and preclinical research conducted by qualified laboratories and research professionals. Purchasers confirm research-use-only intent at checkout. For any clinical application, patients should consult a licensed physician about EGRIFTA SV®, which is a distinct, FDA-approved product.
Every batch is independently tested by a third-party analytical laboratory using high-performance liquid chromatography (HPLC) for purity and mass spectrometry for identity confirmation. The Certificate of Analysis is published on our /coas/ page and linked from the product page by batch number, so each vial can be traced to its specific test report.
Store the lyophilized vial sealed at -20°C in a dry, dark environment until reconstitution. Once reconstituted with bacteriostatic water, refrigerate at 2-8°C and use within the stability window established by the research protocol. Avoid repeat freeze-thaw cycles.
Both are GHRH-receptor agonists, but tesamorelin is a longer 44-amino-acid analog with an N-terminal modification that improves enzymatic stability, while sermorelin is the unmodified 1-29 fragment of native GHRH with a shorter functional half-life. Tesamorelin is FDA-approved as EGRIFTA SV® for a specific clinical indication; sermorelin is not currently approved. Both are supplied by Velora Research as research peptides only — not for human use.
Tesamorelin and ipamorelin act on different receptors. Tesamorelin binds the GHRH receptor on pituitary somatotroph cells; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist with a different signaling profile. In research literature the two are sometimes investigated together to model concurrent GHRH and GHRP signaling. Both are supplied by Velora as research peptides only.
Velora Research accepts international orders for laboratory research use only. Buyers are responsible for ensuring compliance with all applicable local, state, and national regulations in their jurisdiction prior to purchasing.